
The threats to pharmaceutical manufacturer copay programs aren't standing still — and neither should our response to them.
Our President of Patient Affordability, Matthew Turner, recently spoke with @PharmExec at Access USA about the evolving landscape — from accumulators to maximizers to alternative funding programs and what's coming next.
The takeaway? At Paysign, our intelligent program design and unique detection tools are built to identify, adapt, and respond in real-time.
⭐ Visit paysign.com/rx to learn more
📖 Read the full conversation: pharmexec.com/view/next-thre…
English


















